Subscribe To
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma
SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zan...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma
SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zan...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib...
October 10, 2021, 5:00 pm
Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma
SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene Announces BRUKINSA® (Zan...
October 10, 2021, 5:00 pm
Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene (NASDAQ: ...
October 7, 2021, 4:06 pm
Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene (NASDAQ: ...
October 7, 2021, 4:06 pm
Beigene announces first regulatory approval in australia for brukinsa® (zanubrutinib) for treatment of patients with waldenström's macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #BTKi--BeiGene (NASDAQ: ...
October 7, 2021, 4:06 pm